CLASS II ONGOING Drug recall · Reported 26 Feb 2025 · FDA Enforcement Report

Atomoxetine Capsules, USP, 80 mg recalled by Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Inc., U is recalling Atomoxetine Capsules, USP, 80 mg, distributed nationwide in the US. The recall was initiated on 29 Jan 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot Numbers: 19233234, 19233253, Exp.: 7/2025; 19234154, Exp.: 9/2025; 19243185, Exp.: 7/2026; 19243951, 19243974, Exp.: 9/2026.
NDC16714-755, 16714-756, 16714-757, 16714-758, 16714-759, 16714-760
UPC0316714760018, 0316714755014, 0316714756011, 0316714761015, 0316714757018
Quantity recalled58,416 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0243-2025
FDA event ID
96194
Recalling firm
Glenmark Pharmaceuticals Inc., U, Mahwah, NJ
Manufacturer
Northstar Rx LLC
Classification
Class II
Status
Ongoing
Recall initiated
29 Jan 2025
FDA classified
20 Feb 2025
Reported
26 Feb 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity
Drug class
ADHD Medication

Timeline

29 Jan 2025Recall initiated by company
20 Feb 2025Classified by FDA+22 days
26 Feb 2025Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Atomoxetine Capsules, USP, 80 mg, 30 capsule bottles, Rx Only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Glenmark Pharmaceuticals Ltd., Goa, India, NDC 16714-760-01.

Where it was distributed

Nationwide within the U.S

Nationwide

Questions about this recall

Is Atomoxetine Capsules, USP, 80 mg recalled?

Yes. Glenmark Pharmaceuticals Inc., U recalled Atomoxetine Capsules, USP, 80 mg on 29 Jan 2025. The recall is Class II and its status is Ongoing. Recall number D-0243-2025.

Why was it recalled?

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Which lots are affected?

Lot Numbers: 19233234, 19233253, Exp.: 7/2025; 19234154, Exp.: 9/2025; 19243185, Exp.: 7/2026; 19243951, 19243974, Exp.: 9/2026.

Where was it sold?

Nationwide within the U.S

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Glenmark Pharmaceuticals Inc., U

All 141

Other Atomoxetine recalls

All 15